Bioventus, Inc. Class A (BVS)

Over the past six months, Bioventus's stock has experienced fluctuations. As of October 23, 2025, the stock price decreased by 2.36% in the past month and 1.74% in the past three months, but it had risen by 1.46% compared to the previous week, with a 0.29% rise over the month. Key events include reporting Q1 2025 earnings and revenues that surpassed estimates on May 6, 2025, and a new analyst forecast assigning a $15.0 price target on May 7, 2025. On August 4, 2025, the company entered into a new $400 million Senior Secured Credit Agreement. Bioventus reported its Q2 2025 financial results, missing earnings and revenue estimates on August 6, 2025. The company received FDA 510(k) Clearances for two next-generation Peripheral Nerve Stimulation Products on July 30, 2025. Presentations were announced at the Canaccord Genuity 45th Annual Global Growth Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference on August 7, 2025, and September 3, 2025, respectively. Institutional investors experienced a 9.6% loss over the preceding week as of April 8, 2025.

Information explicitly detailing demand seasonality for Bioventus, Inc.'s products and services was not found in the provided search results.

Bioventus, Inc. is a medical technology company focused on active healing, developing and commercializing treatments that enhance the body's natural healing processes. The company operates in the Health Care sector, specifically the Medical/Dental Instruments industry. Its product portfolio includes Pain Treatments, Restorative Therapies, and Surgical Solutions. The Pain Treatments segment offers non-surgical pain injection therapies and PNS products like Durolane, GELSYN-3, SUPARTZ, and Stimrouter. Restorative Therapies focus on minimally invasive fracture treatments, including the EXOGEN Bone Healing System. Surgical Solutions provides bone graft substitutes to stimulate bone healing and ultrasonic products for precise bone cutting and tissue management.

Bioventus is headquartered in Durham, North Carolina, USA, and has a significant global presence with offices in multiple locations including Memphis, Tennessee; Valencia, California; Farmingdale, New York; Mississauga, Ontario, Canada; and Hoofddorp, The Netherlands. The company operates in over 50 countries across North America, Europe, Asia-Pacific, Latin America, and the Middle East. It also has manufacturing and research facilities in the United States and Europe and uses distribution partnerships to make its therapies accessible in more than 90 countries.

Bioventus has maintained a generally positive brand reputation as a "global leader of innovations for active healing." The company's products are recognized for their "safety, innovation, and effectiveness." News releases primarily highlight financial results, product clearances, and participation in industry conferences.

Institutional investors hold a significant portion of Bioventus, Inc. shares, owning 87.93% of the company. Smith & Nephew plc holds a substantial stake of 33.68%. The general public holds a 2.6% stake. Other notable institutional owners include State Street Corp., Schweizerische Nationalbank, and Manulife Financial Corp. John A. Bartholdson, co-founder and partner of Juniper Investment Company, LLC, is also an individual owner.